After years of business and lawsuit-fueled decline, is a Teva turnaround in sight?
For five years, Teva’s stock tumbled amid a potent cocktail of serious and widespread legal allegations, declining company and industry-wide revenue and debt that creaked more heavily each passing year. Now, their CEO and some investors think they can see the light.
Teva released their quarterly earnings report yesterday, and the stock took a 10% jump, to over $13. That’s still a drop in the bucket compared with the years leading up to 2016, when the stock briefly pushed past $70, but a noticeable bump after a half-decade of almost direct decline.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.